Phase IB/II Open-label Single Arm Study to Evaluate Safety and Efficacy of Tucatinib in Combination With Palbociclib and Letrozole in Subjects With Hormone Receptor Positive and HER2-positive Metastatic Breast Cancer
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Letrozole (Primary) ; Palbociclib (Primary) ; Tucatinib (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Sep 2017 Planned initiation date changed from 1 Aug 2017 to 1 Oct 2017.
- 06 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Aug 2017.
- 21 Apr 2017 Planned initiation date changed from 1 Mar 2017 to 1 Jun 2017.